Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
Status:
Completed
Trial end date:
2017-08-18
Target enrollment:
Participant gender:
Summary
This study involves research about an investigational medicine called Amlexanox. The reason
for this study is to find out how Amlexanox can improve type 2 diabetes, insulin resistance,
obesity and non-alcoholic fatty liver disease (NAFLD). In this study, Amlexanox is considered
to be investigational (not approved by the Food and Drug Administration [FDA]) for type 2
diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). This is
a placebo controlled study. There is a 50-50 chance that the patient may either receive the
study drug, Amlexanox, or a placebo (sugar pill). Neither the patient or the study doctors
will know if the patient is receiving the study drug or placebo.